ZOBUXA- enrofloxacin tablet
Zobuxa by
Drug Labeling and Warnings
Zobuxa by is a Animal medication manufactured, distributed, or labeled by Elanco US Inc., Elanco, France SAS, Mylan Laboratories Limited (Unit-1), Allpack Group AG. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
- SPL UNCLASSIFIED SECTION
-
DESCRIPTION:
Enrofloxacin is a synthetic chemotherapeutic agent from the class of the quinolone carboxylic acid derivatives. It has antibacterial activity against a broad spectrum of Gram negative and Gram positive bacteria (See Tables I and II). It is rapidly absorbed from the digestive tract, penetrating into all measured body tissues and fluids (See Table III). Tablets are available in four tablet sizes (22.7, 68, 136 and 272 mg enrofloxacin).
- CHEMICAL NOMENCLATURE AND STRUCTURAL FORMULA:
-
ACTIONS:
Microbiology: Quinolone carboxylic acid derivatives are classified as DNA gyrase inhibitors. The mechanism of action of these compounds is very complex and not yet fully understood. The site of action is bacterial gyrase, a synthesis promoting enzyme. The effect on Escherichia coli is the inhibition of DNA synthesis through prevention of DNA supercoiling. Among other things, such compounds lead to the cessation of cell respiration and division. They may also interrupt bacterial membrane integrity. 1 Enrofloxacin is bactericidal, with activity against both Gram negative and Gram positive bacteria. The minimum inhibitory concentrations (MICs) were determined for a series of 39 isolates representing 9 genera of bacteria from natural infections in dogs and cats, selected principally because of resistance to one or more of the following antibiotics: ampicillin, cephalothin, colistin, chloramphenicol, erythromycin, gentamicin, kanamycin, penicillin, streptomycin, tetracycline, triple sulfa and sulfa/trimethoprim. The MIC values for enrofloxacin against these isolates are presented in Table I. Most strains of these organisms were found to be susceptible to enrofloxacin in vitro but the clinical significance has not been determined for some of the isolates.
The susceptibility of organisms to enrofloxacin should be determined using enrofloxacin 5 mcg disks. Specimens for susceptibility testing should be collected prior to the initiation of enrofloxacin therapy.
TABLE I - MIC Values for Enrofloxacin Against Canine and Feline Pathogens (Diagnostic laboratory isolates, 1984) *Includes feline isolates.
Organisms Isolates MIC Range (mcg/mL) Bacteroides spp. 2 2 Bordetella bronchiseptica 3 0.125-0.5 Brucella canis 2 0.125-0.25 Clostridium perfringens 1 0.5 Escherichia coli 5* ≤0.016-0.031 Klebsiella spp. 11* 0.031-0.5 Proteus mirabilis 6 0.062-0.125 Pseudomonas aeruginosa 4 0.5-8 Staphylococcus spp. 5 0.125 The inhibitory activity on 120 isolates of seven canine urinary pathogens was also investigated and is listed in Table II.
TABLE II - MIC Values for Enrofloxacin Against Canine Urinary Pathogens (Diagnostic laboratory isolates, 1985) Organisms Isolates MIC Range (mcg/mL) E. coli 30 0.06-2.0 P. mirabilis 20 0.125-2.0 K. pneumoniae 20 0.06-0.5 P. aeruginosa 10 1.0-8.0 Enterobacter spp. 10 0.06-1.0 Staph. (coag. +) 20 0.125-0.5 Strep. (alpha hemol.) 10 0.5-8.0 Distribution in the Body: Enrofloxacin penetrates into all canine and feline tissues and body fluids. Concentrations of drug equal to or greater than the MIC for many pathogens (See Tables I, II and III) are reached in most tissues by two hours after dosing at 2.5 mg/kg and are maintained for 8-12 hours after dosing. Particularly high levels of enrofloxacin are found in urine. A summary of the body fluid/tissue drug levels at 2 to 12 hours after dosing at 2.5 mg/kg is given in Table III.
TABLE III - Body Fluid/Tissue Distribution of Enrofloxacin in Dogs and Cats Single Oral Dose = 2.5 mg/kg (1.13 mg/lb) Body Fluids (mcg/mL) Post-treatment Enrofloxacin Levels Canine (n=2) Feline (n=4) 2 Hr. 8 Hr. 2 Hr. 12 Hr. Bile - - 2.13 1.97 Cerebrospinal Fluid - - 0.37 0.10 Urine 43.05 55.35 12.81 26.41 Eye Fluids 0.53 0.66 0.45 0.65 Whole Blood 1.01 0.36 - - Plasma 0.67 0.33 - - Serum - - 0.48 0.18 Tissues (mcg/g) Hematopoietic System Liver 3.02 1.36 1.84 0.37 Spleen 1.45 0.85 1.33 0.52 Bone Marrow 2.10 1.22 1.68 0.64 Lymph Node 1.32 0.91 0.49 0.21 Urogenital System Kidney 1.87 0.99 1.43 0.37 Bladder Wall 1.36 0.98 1.16 0.55 Testes 1.36 1.10 1.01 0.28 Prostate 1.36 2.20 1.88 0.55 Ovaries - - 0.78 0.56 Uterine Wall 1.59 0.29 0.81 1.05 Gastrointestinal and Cardiopulmonary Systems Lung 1.34 0.82 0.91 0.33 Heart 1.88 0.78 0.84 0.32 Stomach 3.24 2.16 3.26 0.27 Small Intestine 2.10 1.11 2.72 0.40 Large Intestine - - 0.94 1.10 Other Fat 0.52 0.40 0.24 0.11 Skin 0.66 0.48 0.46 0.17 Muscle 1.62 0.77 0.53 0.29 Brain 0.25 0.24 0.22 0.12 Mammary Gland 0.45 0.21 0.36 0.30 Feces 1.65 9.97 0.37 4.18 Pharmacokinetics: In dogs, the absorption and elimination characteristics of the oral formulation are linear (plasma concentrations increase proportionally with dose) when enrofloxacin is administered at up to 11.5 mg/kg, twice daily. 2 Approximately 80% of the orally administered dose enters the systemic circulation unchanged. The eliminating organs, based on the drug‘s body clearance time, can readily remove the drug with no indication that the eliminating mechanisms are saturated. The primary route of excretion is via the urine. The absorption and elimination characteristics beyond this point are unknown. In cats, no oral absorption information is available at other than 2.5 mg/kg, administered orally as a single dose. Saturable absorption and/or elimination processes may occur at greater doses. When saturation of the absorption process occurs, the plasma concentration of the active moiety will be less than predicted, based on the concept of dose proportionality.
Following an oral dose in dogs of 2.5 mg/kg (1.13 mg/lb) enrofloxacin reached 50% of its maximum serum concentration in 15 minutes and peak serum level was reached in one hour. The elimination half-life in dogs is approximately 2½-3 hours at that dose, while in cats it is greater than 4 hours. In a study comparing dogs and cats, the peak concentration and the time to peak concentration were not different. A graph indicating the mean serum levels following a dose of 2.5 mg/kg (1.13 mg/lb) in dogs (oral and intramuscular) and cats (oral) is shown in Figure 1.
Figure 1 - Serum Concentrations of Enrofloxacin Following a Single Oral or Intramuscular Dose at 2.5 mg/kg in Dogs and a Single Oral Dose at 2.5 mg/kg in Cats.
Breakpoint: Based on pharmacokinetic studies of enrofloxacin in dogs and cats after a single oral administration of 2.5 mg enrofloxacin/kg BW (i.e. half of the lowest-end single daily dose range for dogs and half the single daily dose for cats) and the data listed in Tables I and II, the following breakpoints are recommended for canine and feline isolates.
Zone Diameter (mm) MIC (μg/mL) Interpretation ≥21 ≤ 0.5 Susceptible (S) 18 - 20 1 Intermediate (I) ≤ 17 ≥2 Resistant (R) A report of “Susceptible” indicates that the pathogen is likely to be inhibited by generally achievable plasma levels. A report of “Intermediate” is a technical buffer and isolates falling into this category should be retested. Alternatively the organism may be successfully treated if the infection is in a body site where drug is physiologically concentrated. A report of “Resistant” indicates that the achievable drug concentrations are unlikely to be inhibitory and other therapy should be selected.
Standardized procedures require the use of laboratory control organisms for both standardized disk diffusion assays and standardized dilution assays. The 5 μg enrofloxacin disk should give the following zone diameters and enrofloxacin powder should provide the following MIC values for reference strains.
QC strain MIC (μg/mL) Zone Diameter (mm) E. coli ATCC 25922 0.008 - 0.03 32 - 40 P. aeruginosa ATCC 27853 1 - 4 15 - 19 S. aureus ATCC 25923 27 - 31 S. aureus ATCC 29213 0.03 - 0.12 - INDICATIONS:
-
EFFICACY CONFIRMATION:
Dogs: Clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus intermedius; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of Escherichia coli and Staphylococcus aureus; and urinary cystitis associated with susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus aureus.
-
CONTRAINDICATIONS:
Enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones.
Dogs: Based on the studies discussed under the section on Animal Safety Summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). The safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. Large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. In clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. However, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.
-
ADVERSE REACTIONS:
Dogs: Two of the 270 (0.7%) dogs treated with enrofloxacin tablets at 5.0 mg/kg per day in the clinical field studies exhibited side effects, which were apparently drug-related. These two cases of vomition were self-limiting.
Post-Approval Experience: The following adverse experiences, although rare, are based on voluntary post-approval adverse drug experience reporting. The categories of reactions are listed in decreasing order of frequency by body system.
Gastrointestinal: anorexia, diarrhea, vomiting, elevated liver enzymes Neurologic: ataxia, seizures
Behavioral: depression, lethargy, nervousness
Cats: No drug-related side effects were reported in 124 cats treated with enrofloxacin tablets at 5.0 mg/kg per day for 10 days in clinical field studies.
Post-Approval Experience: The following adverse experiences, although rare, are based on voluntary post-approval adverse drug experience reporting. The categories of reactions are listed in decreasing order of frequency by body system.
Ocular: Mydriasis, retinal degeneration (retinal atrophy, attenuated retinal vessels, and hyperreflective tapeta have been reported), loss of vision. Mydriasis may be an indication of impending or existing retinal changes.
Gastrointestinal: vomiting, anorexia, elevated liver enzymes, diarrhea Neurologic: ataxia, seizures
Behavioral: depression, lethargy, vocalization, aggression
For medical emergencies or to report adverse reactions, call 1-888-545-5973.
-
ANIMAL SAFETY SUMMARY:
Dogs: Adult dogs receiving enrofloxacin orally at a daily dosage rate of 52 mg/kg for 13 weeks had only isolated incidences of vomition and inappetence. Adult dogs receiving the tablet formulation for 30 consecutive days at a daily treatment of 25 mg/kg did not exhibit significant clinical signs nor were there effects upon the clinical chemistry, hematological or histological parameters. Daily doses of 125 mg/kg for up to 11 days induced vomition, inappetence, depression, difficult locomotion and death while adult dogs receiving 50 mg/kg/day for 14 days had clinical signs of vomition and inappetence.
Adult dogs dosed intramuscularly for three treatments at 12.5 mg/kg followed by 57 oral treatments at 12.5 mg/kg, all at 12 hour intervals, did not exhibit either significant clinical signs or effects upon the clinical chemistry, hematological or histological parameters.
Oral treatment of 15 to 28 week old growing puppies with daily dosage rates of 25 mg/kg has induced abnormal carriage of the carpal joint and weakness in the hindquarters. Significant improvement of clinical signs is observed following drug withdrawal. Microscopic studies have identified lesions of the articular cartilage following 30 day treatments at either 5, 15 or 25 mg/kg in this age group. Clinical signs of difficult ambulation or associated cartilage lesions have not been observed in 29 to 34 week old puppies following daily treatments of 25 mg/kg for 30 consecutive days nor in 2 week old puppies with the same treatment schedule.
Tests indicated no effect on circulating microfilariae or adult heartworms (Dirofilaria immitis) when dogs were treated at a daily dosage rate of 15 mg/kg for 30 days. No effect on cholinesterase values was observed.
No adverse effects were observed on reproductive parameters when male dogs received 10 consecutive daily treatments of 15 mg/kg/day at 3 inter- vals (90, 45 and 14 days) prior to breeding or when female dogs received 10 consecutive daily treatments of 15 mg/kg/day at 4 intervals; between 30 and 0 days prior to breeding, early pregnancy (between 10th & 30th days), late pregnancy (between 40th & 60th days), and during lactation (the first 28 days).
Cats: Cats in age ranges of 3 to 4 months and 7 to 10 months received daily treatments of 25 mg/kg for 30 consecutive days with no adverse effects upon the clinical chemistry, hematological or histological parameters. In cats 7-10 months of age treated daily for 30 consecutive days, 2 of 4 receiving 5 mg/kg, 3 of 4 receiving 15 mg/kg, 2 of 4 receiving 25 mg/kg and 1 of 4 nontreated controls experienced occasional vomition. Five to 7 month old cats had no side effects with daily treatments of 15 mg/kg for 30 days, but 2 of 4 animals had articular cartilage lesions when administered 25 mg/kg/day for 30 days.
Doses of 125 mg/kg for 5 consecutive days to adult cats induced vomition, depression, incoordination and death while those receiving 50 mg/kg for 6 days had clinical signs of vomition, inappetence, incoordination and convulsions, but they returned to normal.
Enrofloxacin was administered to thirty-two (8 per group), six- to eight- month-old cats at doses of 0, 5, 20, and 50 mg/kg of body weight once a day for 21 consecutive days. There were no adverse effects observed in cats that received 5 mg/kg body weight of enrofloxacin. The administration of enrofloxacin at 20 mg/kg body weight or greater caused salivation, vomition, and depression. Additionally, dosing at 20 mg/kg body weight or greater resulted in mild to severe fundic lesions on ophthalmologic examination (change in color of the fundus, central or generalized retinal degeneration), abnormal electroretinograms (including blindness), and diffuse light microscopic changes in the retina.
-
DRUG INTERACTIONS:
Compounds that contain metal cations (e.g., aluminum, calcium, iron, magnesium) may reduce the absorption of some quinolone-class drugs from the intestinal tract. Concomitant therapy with other drugs that are metabolized in the liver may reduce the clearance rates of the quinolone and the other drug.
Dogs: Enrofloxacin has been administered to dogs at a daily dosage rate of 10 mg/kg concurrently with a wide variety of other health products including anthelmintics (praziquantel, febantel, sodium disophenol), insecticides (fenthion, pyrethrins), heartworm preventatives (diethylcarbamazine) and other antibiotics (ampicillin, gentamicin sulfate, penicillin, dihydrostreptomycin). No incompatibilities with other drugs are known at this time.
-
WARNINGS:
For use in animals only. In rare instances, use of this product in cats has been associated with Retinal Toxicity. Do not exceed 5 mg/kg of body weight per day in cats. Safety in breeding or pregnant cats has not been established. Keep out of reach of children.
Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposure. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight.
For customer service or to obtain product information, including Material Safety Data Sheet, call 1-888-545-5973.
-
PRECAUTIONS:
Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures.
Quinolone-class drugs have been associated with cartilage erosions in weight-bearing joints and other forms of arthropathy in immature animals of various species.
The use of fluoroquinolones in cats has been reported to adversely effect the retina. Such products should be used with caution in cats.
-
DOSAGE AND ADMINISTRATION:
Dogs: Administer orally at a rate to provide 5-20 mg/kg (2.27 to 9.07 mg/lb) of body weight. Selection of a dose within this range should be based on clinical experience, the severity of disease, and susceptibility of the pathogen. Animals which receive doses in the upper-end of the dose range should be carefully monitored for clinical signs that may include inappetence, depression, and vomition.
Weight of Dog Once Daily Dosing Chart 5 mg/kg 10 mg/kg 15 mg/kg 20 mg/kg 9.1 kg (20 lb) 2 x 22.7 mg tablets 1 x 22.7 mg plus
1 x 68 mg tablets1 x 136 mg tablet or
0.5 x 272 mg tablet1 x 136 mg plus
2 x 22.7 mg tablets or
0.5 x 272 mg plus 2 x 22.7 mg tablet27.2 kg (60 lb) 1 x 136 mg tablet or
0.5 x 272 mg tablet2 x 136 mg tablets or
1 x 272 mg tablet3 x 136 mg tablets or
1.5 x 272 mg tablets4 x 136 mg tablets or
2 x 272 mg tablets54.4 kg (120 lb) 2 x 136 mg tablets or
1 x 272 mg tablets4 x 136 mg tablets or
2 x 272 mg tablets6 x 136 mg tablets or
3 x 272 mg tablets8 x 136 mg tablets or
4 x 272 mg tabletsAll tablet sizes are doubled scored (a score on either side of the tablet) for accurate dosing.
Cats: Administer orally at 5 mg/kg (2.27 mg/lb) of body weight. The dose for dogs and cats may be administered either as a single daily dose or divided into two (2) equal daily doses administered at twelve (12) hour intervals. The dose should be continued for at least 2-3 days beyond cessation of clinical signs, to a maximum of 30 days.
Weight of Cat Once Daily Dosing Chart (5 mg/kg/day) 5 lb (2.27 kg) 1/2 x 22.7 mg tablet 10 lb (4.5 kg) 1 x 22.7 mg tablet 15 lb (6.8 kg) 1 and 1/2 x 22.7 mg tablets or
1/2 x 68 mg tabletAll tablet sizes are doubled scored (a score on either side of the tablet) for accurate dosing.
Dogs & Cats: The duration of treatment should be selected based on clinical evidence. Generally, administration of Zobuxa Tablets should continue for at least 2-3 days beyond cessation of clinical signs. For severe and/or complicated infections, more prolonged therapy, up to 30 days, may be required. If no improvement is seen within five days, the diagnosis should be reevaluated and a different course of therapy considered.
The lower limit of the dose range in dogs and the daily dose for cats was based on efficacy studies in dogs and cats where enrofloxacin was administered at 2.5 mg/kg twice daily. Target animal safety and toxicology were used to establish the upper limit of the dose range for dogs and treatment duration for dogs and cats.
- STORAGE:
- HOW SUPPLIED:
-
REFERENCES:
1 Doughherty, T.J., & Saukkonen, J.J. (1985). Membrane permeability changes associated with DNA gyrase inhibitors in Escherichia Coli. Antimicrob Agents Chemother, 28 (2), 200-206
2 Walker, R.D. et al. Dec 1992. Pharmacokinetic Evaluation of Enrofloxacin Administered Orally to Healthy Dogs. Am. J. Res. V 53(12):2315-2319. Nov 2016
Manufactured for: Elanco US Inc. 2500 Innovation Way Greenfield, IN 46140 Product of India ANADA # 200-517, Approved by FDA Elanco, Zobuxa and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.
ElancoTM
- Principal Display Panel - Zobuxa 22.7 mg 100 Tablets Bottle Label
- Principal Display Panel - Zobuxa 22.7 mg 100 Tablets Carton Label
- Principal Display Panel - Zobuxa 22.7 mg 500 Tablets Bottle Label
- Principal Display Panel - Zobuxa 22.7 mg 500 Tablets Carton Label
- Principal Display Panel - Zobuxa 68 mg 50 Tablets Bottle Label
- Principal Display Panel - Zobuxa 68 mg 50 Tablets Carton Label
- Principal Display Panel - Zobuxa 68 mg 150 Tablets Bottle Label
- Principal Display Panel - Zobuxa 68 mg 150 Tablets Carton Label
- Principal Display Panel - Zobuxa 136 mg 50 Tablets Bottle Label
- Principal Display Panel - Zobuxa 136 mg 50 Tablets Carton Label
- Principal Display Panel - Zobuxa 272 mg 50 Tablets Bottle Label
- Principal Display Panel - Zobuxa 272 mg 50 Tablets Carton Label
-
INGREDIENTS AND APPEARANCE
ZOBUXA
enrofloxacin tabletProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 58198-5570 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength enrofloxacin (UNII: 3DX3XEK1BN) (enrofloxacin - UNII:3DX3XEK1BN) enrofloxacin 22.7 mg Inactive Ingredients Ingredient Name Strength LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) POVIDONE, UNSPECIFIED (UNII: FZ989GH94E) CROSCARMELLOSE SODIUM (UNII: M28OL1HH48) MAGNESIUM STEARATE (UNII: 70097M6I30) Product Characteristics Color BROWN (beige, slightly speckled) Score no score Shape ROUND (ROUND) Size 6mm Flavor Imprint Code NA;AK Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 58198-5570-1 1 in 1 BOTTLE, UNIT-DOSE 1 100 in 1 BOTTLE, PLASTIC 2 NDC: 58198-5570-2 1 in 1 BOTTLE, UNIT-DOSE 2 500 in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANADA ANADA200517 08/12/2014 ZOBUXA
enrofloxacin tabletProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 58198-5578 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength enrofloxacin (UNII: 3DX3XEK1BN) (enrofloxacin - UNII:3DX3XEK1BN) enrofloxacin 68 mg Inactive Ingredients Ingredient Name Strength LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) POVIDONE, UNSPECIFIED (UNII: FZ989GH94E) CROSCARMELLOSE SODIUM (UNII: M28OL1HH48) MAGNESIUM STEARATE (UNII: 70097M6I30) Product Characteristics Color BROWN (beige, slightly speckled) Score no score Shape ROUND (ROUND) Size 9mm Flavor Imprint Code NA;AK Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 58198-5578-1 1 in 1 BOTTLE, UNIT-DOSE 1 50 in 1 BOTTLE, PLASTIC 2 NDC: 58198-5578-2 1 in 1 BOTTLE, UNIT-DOSE 2 150 in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANADA ANADA200517 08/12/2014 ZOBUXA
enrofloxacin tabletProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 58198-5572 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength enrofloxacin (UNII: 3DX3XEK1BN) (enrofloxacin - UNII:3DX3XEK1BN) enrofloxacin 136 mg Inactive Ingredients Ingredient Name Strength LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) POVIDONE, UNSPECIFIED (UNII: FZ989GH94E) CROSCARMELLOSE SODIUM (UNII: M28OL1HH48) MAGNESIUM STEARATE (UNII: 70097M6I30) Product Characteristics Color BROWN (beige, slightly speckled) Score no score Shape ROUND (ROUND) Size 11mm Flavor Imprint Code NA;AK Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 58198-5572-1 1 in 1 BOTTLE, UNIT-DOSE 1 50 in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANADA ANADA200517 08/12/2014 ZOBUXA
enrofloxacin tabletProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 58198-5576 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength enrofloxacin (UNII: 3DX3XEK1BN) (enrofloxacin - UNII:3DX3XEK1BN) enrofloxacin 272 mg Inactive Ingredients Ingredient Name Strength LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) POVIDONE, UNSPECIFIED (UNII: FZ989GH94E) CROSCARMELLOSE SODIUM (UNII: M28OL1HH48) MAGNESIUM STEARATE (UNII: 70097M6I30) Product Characteristics Color BROWN (beige, slightly speckled) Score no score Shape ROUND (ROUND) Size 13mm Flavor Imprint Code NA;AK Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 58198-5576-1 1 in 1 BOTTLE, UNIT-DOSE 1 50 in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANADA ANADA200517 08/12/2014 Labeler - Elanco US Inc, (966985624) Establishment Name Address ID/FEI Business Operations Allpack Group AG 484572565 PACK
Trademark Results [Zobuxa]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ZOBUXA 77715577 4299657 Live/Registered |
Novartis AG 2009-04-16 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.